Monoclonal Antibody Found 75.9% Effective Against RSV-related Hospitalization

A Short Communication published by the journal Influenza and Other Respiratory Diseases added to the research-based and real-world evidence the respiratory syncytial virus (RSV) can be prevented in most infants receiving a new monoclonal antibody (mAb). 

RSV is the #1 cause of hospitalization of infants in most countries. In France, hospitalizations with RSV represent 28% of all-cause hospitalizations in children under the age of one during the RSV season. 

This new study found a single dose of the extended half-life Beyfortus™ (nirsevimab) was found to be 75.9% effective against RSV-related hospitalization in France.

This long-duration mAb was also 80.6% (61.6–90.3) and 80.4% (61.7–89.9) effective in two sensitivity analyses.

These real-world estimates confirmed the efficacy observed in RSV clinical studies, wrote these researchers on June 5, 2024.

Sanofi and AstraZeneca recently announced they are producing Beyfortus before the 2024-2025 RSV season in the U.S. 

On November 16, 2023, the CDC announced the release of the U.S. FDA-approved Beyfortus to physicians and hospitals through the Federal VFC Program and commercial channels.